Core Laboratories (CLB) Q4 2023 earnings summary

Executive summary

• Q4 2023 revenue was $128.2M, up 2% sequentially; adjusted operating income was $15.0M and adjusted EPS was $0.19. FY revenue rose 4%, with adjusted EPS growth of 40%.

• Strong international Reservoir Description demand supported results, while Middle East disruptions affected assay work; debt reduction and improved ROIC remained priorities.

Financial highlights

• Q4 GAAP operating income was $14.6M and diluted EPS was $0.14; adjusted operating income was $15.0M and adjusted EPS was $0.19, down 6% and 14% sequentially, respectively.

• FY 2023 revenue was $509.8M, up 4%; GAAP operating income was $54.6M versus $41.5M in 2022, while adjusted operating income was $61.2M, up 36%.

• FY GAAP diluted EPS attributable to shareholders was $0.86 versus $0.42 in 2022; adjusted EPS was $0.80, up 40%.

• FY net income attributable to shareholders was $40.9M versus $19.5M in 2022; Q4 was $6.5M versus $6.8M in Q4 2022.

Outlook and guidance

• Q1 2024 revenue guidance is $122M–$128M, operating income $11.8M–$14.3M, operating margin ~10%, and EPS $0.14–$0.18; guidance excludes FX gains and losses and assumes a 20% tax rate.

• Q1 Reservoir Description revenue is projected at $80M–$84M and operating income at $10.1M–$11.9M; Production Enhancement revenue is projected at $42M–$44M and operating income at $1.5M–$2.2M.

• Typical seasonal patterns point to lower Q1 activity in some regions; Reservoir Description revenue is expected down low- to mid-single digits. January freezing conditions hurt U.S. activity, with improvement expected as the quarter progresses.

• International upstream projects support expected year-over-year growth; U.S. onshore drilling and completion activity is expected flat in 2024, while proprietary diagnostics and energetic systems are projected to outperform activity levels.